SCHEMBL6691355

SCHEMBL6691355

CC(C)(C)OC(=O)N1CC(O)CC1C(=O)N1CCC(Cc2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
KCNH2 Q12809 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
CYP2C19 P33261 3/20 0.44
CYP2C9 P11712 2/20 0.44
MAPK14 Q16539 2/20 0.44
HTR2B P41595 1/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7142421 1.00 ALDH1A1 (0.46) ALDH1A1L3MBTL1KCNH2HRH3LMNA
SCHEMBL7139747 0.88 UCHL1 (0.47) ALDH1A1L3MBTL1KCNH2HRH3LMNA
SCHEMBL7143741 0.88 UCHL1 (0.47) ALDH1A1L3MBTL1KCNH2HRH3LMNA
SCHEMBL6907072 0.85 POLB (0.52) L3MBTL1SMN1; SMN2CYP2C19POLB
SCHEMBL6679116 0.85 TACR3 (0.51) ALDH1A1L3MBTL1LMNAMAPTSMN1; SMN2
SCHEMBL6661762 0.84 HSD17B10 (0.63) CYP2C19CYP2C9MAPK14HTR2B
SCHEMBL6663316 0.84 HSD17B10 (0.63) CYP2C19CYP2C9MAPK14HTR2B
SCHEMBL6655904 0.84 HSD17B10 (0.63) CYP2C19CYP2C9MAPK14HTR2B
SCHEMBL22123338 0.84 POLB (0.50) SMN1; SMN2CYP2C19CYP1A2POLBCYP3A4
SCHEMBL22123085 0.84 POLB (0.50) SMN1; SMN2CYP2C19CYP1A2POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1257544-B1 PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE VERTEX PHARMA (US) 2012-07-25 EP disclosed
EP-1441728-A2 MODULATORS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY Vertex Pharmaceuticals Incorporated (US) 2004-08-04 EP disclosed
US-20040034019-A1 Piperazine and piperidine derivatives VERTEX PHARMACEUTICALS INCORPORATED 2004-02-19 US disclosed
US-20030191110-A1 Modulators of the cholesterol biosynthetic pathway VERTEX PHARMACEUTICALS, INCORPORATED 2003-10-09 US disclosed
WO-2003037338-A2 MODULATORS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-05-08 WO disclosed
EP-1257544-A2 PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE Vertex Pharmaceuticals Incorporated (US) 2002-11-20 EP disclosed
WO-2001058891-A2 PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE VERTEX PHARMACEUTICALS INCORPORATED (US) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034019-A1 Piperazine and piperidine derivatives GAP43, BDNF, NGF ALDH1A1 1047/4885L3MBTL1 4374/4885KCNH2 93/4885
US-20030191110-A1 Modulators of the cholesterol biosynthetic pathway SREBF2, SREBF1, CYP46A1 ALDH1A1 2371/4885L3MBTL1 935/4885KCNH2 4738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.